Patents Expiring in December 2034
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | |||
| Zealand Pharma | ZEGALOGUE | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-001 | Mar 22, 2021 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING DIABETIC HYPOGLYCEMIA | ||||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING DIABETIC HYPOGLYCEMIA | ||||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-001 | Aug 27, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-004 | Feb 16, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-002 | Aug 27, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-003 | Aug 27, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
